Please provide your email address to receive an email when new articles are posted on . MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK-positive non-small cell lung ...
What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...
Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. High intratumoral tryptophan metabolism is a poor predictor of response to ...
Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy. ALK-positive disease accounts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results